Alan Mendelowitz

1.6k total citations
20 papers, 1.1k citations indexed

About

Alan Mendelowitz is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Alan Mendelowitz has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 3 papers in Pharmacology and 3 papers in Clinical Psychology. Recurrent topics in Alan Mendelowitz's work include Schizophrenia research and treatment (10 papers), Electroconvulsive Therapy Studies (7 papers) and Bipolar Disorder and Treatment (4 papers). Alan Mendelowitz is often cited by papers focused on Schizophrenia research and treatment (10 papers), Electroconvulsive Therapy Studies (7 papers) and Bipolar Disorder and Treatment (4 papers). Alan Mendelowitz collaborates with scholars based in United States, United Kingdom and Czechia. Alan Mendelowitz's co-authors include Delbert G. Robinson, Margaret G. Woerner, Marjorie McMeniman, Robert M. Bilder, Nina R. Schooler, John M. Kane, Samuel H. Bailine, Georgios Petrides, Raphael J. Braga and Chitra Malur and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Schizophrenia Bulletin.

In The Last Decade

Alan Mendelowitz

20 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Mendelowitz United States 12 903 282 251 185 104 20 1.1k
Haranath Parepally United States 16 986 1.1× 204 0.7× 320 1.3× 107 0.6× 141 1.4× 24 1.2k
Seema Quraishi United Kingdom 14 1.0k 1.1× 177 0.6× 239 1.0× 98 0.5× 194 1.9× 20 1.2k
Monika Edlinger Austria 14 710 0.8× 217 0.8× 217 0.9× 76 0.4× 84 0.8× 33 875
Mihai Gheorghe Romania 4 802 0.9× 219 0.8× 188 0.7× 129 0.7× 67 0.6× 4 910
Daniel Bergé Spain 17 534 0.6× 145 0.5× 247 1.0× 101 0.5× 253 2.4× 67 920
Berna Binnur Akdede Türkiye 17 788 0.9× 178 0.6× 318 1.3× 84 0.5× 219 2.1× 58 1.1k
Aygün Ertuğrul Türkiye 17 573 0.6× 96 0.3× 213 0.8× 95 0.5× 198 1.9× 54 962
Rebecca Schennach Germany 20 458 0.5× 85 0.3× 285 1.1× 102 0.6× 95 0.9× 37 830
S. R. Marder United States 11 638 0.7× 260 0.9× 263 1.0× 60 0.3× 74 0.7× 19 799
Anna Mané Spain 18 583 0.6× 106 0.4× 149 0.6× 106 0.6× 222 2.1× 70 902

Countries citing papers authored by Alan Mendelowitz

Since Specialization
Citations

This map shows the geographic impact of Alan Mendelowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Mendelowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Mendelowitz more than expected).

Fields of papers citing papers by Alan Mendelowitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Mendelowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Mendelowitz. The network helps show where Alan Mendelowitz may publish in the future.

Co-authorship network of co-authors of Alan Mendelowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Mendelowitz. A scholar is included among the top collaborators of Alan Mendelowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Mendelowitz. Alan Mendelowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, Brian J., Henrique Lemos, Nina R. Schooler, et al.. (2023). Longitudinal study of inflammation and relapse in schizophrenia. Schizophrenia Research. 252. 88–95. 7 indexed citations
2.
Braga, Raphael J., Majnu John, Nina R. Schooler, et al.. (2019). Continuation Electroconvulsive Therapy for Patients With Clozapine-Resistant Schizophrenia. Journal of Ect. 35(3). 156–160. 16 indexed citations
3.
Petrides, Georgios, Chitra Malur, Raphael J. Braga, et al.. (2019). Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. FOCUS The Journal of Lifelong Learning in Psychiatry. 17(1). 76–82. 6 indexed citations
4.
Pillai, Anilkumar, Nina R. Schooler, Stephen W. Looney, et al.. (2017). Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. Schizophrenia Research. 193. 263–268. 17 indexed citations
5.
Braga, Raphael J., Georgios Petrides, Nina R. Schooler, et al.. (2017). 761. Continuation Electroconvulsive Therapy for Clozapine-Resistant Schizophrenia. Biological Psychiatry. 81(10). S309–S309. 2 indexed citations
6.
Buckley, P.F., Nina R. Schooler, Donald Goff, et al.. (2016). Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatric Services. 67(12). 1370–1372. 5 indexed citations
7.
Petrides, Georgios, Chitra Malur, Raphael J. Braga, et al.. (2014). Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study. American Journal of Psychiatry. 172(1). 52–58. 214 indexed citations
8.
Wang, Ying, et al.. (2014). Olanzapine for the Treatment of Psychiatric Illness and Urticaria: A Case Report. Psychosomatics. 55(6). 735–738. 1 indexed citations
9.
Buckley, P.F., Nina R. Schooler, Donald Goff, et al.. (2014). Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. Schizophrenia Bulletin. 41(2). 449–459. 56 indexed citations
10.
Roy, Durga, Pamela Hoffman, Melissa M. Dudas, & Alan Mendelowitz. (2013). Pharmacologic Management of Aggression in Adults with Intellectual Disability. Journal of Intellectual Disability - Diagnosis and Treatment. 1(1). 28–43. 2 indexed citations
11.
Robinson, Delbert G., Margaret G. Woerner, Barbara Napolitano, et al.. (2006). Randomized Comparison of Olanzapine Versus Risperidone for the Treatment of First-Episode Schizophrenia: 4-Month Outcomes. American Journal of Psychiatry. 163(12). 2096–2102. 86 indexed citations
12.
Mendelowitz, Alan. (2004). The Utility of Intramuscular Ziprasidone in the Management of Acute Pswychotic Agitation. Annals of Clinical Psychiatry. 16(3). 145–154. 18 indexed citations
13.
Robinson, Delbert G., Margaret G. Woerner, Marjorie McMeniman, Alan Mendelowitz, & Robert M. Bilder. (2004). Symptomatic and Functional Recovery From a First Episode of Schizophrenia or Schizoaffective Disorder. American Journal of Psychiatry. 161(3). 473–479. 458 indexed citations
14.
Trivedi, Harsh, Alan Mendelowitz, & Max Fink. (2003). Gilles de la Tourette Form of Catatonia: Response to ECT. Journal of Ect. 19(2). 115–117. 33 indexed citations
15.
Weiden, Peter J., Naveed Iqbal, Alan Mendelowitz, et al.. (2002). Best Clinical Practice with Ziprasidone: Update After One Year of Experience. Journal of Psychiatric Practice. 8(2). 81–97. 33 indexed citations
16.
Levin, Tomer T., Jonathan Barrett, & Alan Mendelowitz. (2002). Death From Clozapine-Induced Constipation: Case Report and Literature Review. Psychosomatics. 43(1). 71–73. 52 indexed citations
17.
Sher, Leo & Alan Mendelowitz. (1999). Case Report of Dramatic Resolution of Psychotic Symptoms During Cross-Over to Clozapine. The Medicine Forum. 14(2). 1 indexed citations
18.
Mendelowitz, Alan, J.A. Lieberman, A. Koreen, et al.. (1996). Incidence of suicide in a research study of first episode schizophrenia. Biological Psychiatry. 39(7). 521–521. 2 indexed citations
19.
Mendelowitz, Alan, et al.. (1995). Clozapine-Induced Agranulocytosis. CNS Drugs. 4(6). 412–421. 19 indexed citations
20.
Lavin, Michael R., Alan Mendelowitz, & Michael H. Kronig. (1993). Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biological Psychiatry. 34(3). 146–151. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haranath Parepally Breakdown of academic impact, for papers by Seema Quraishi Breakdown of academic impact, for papers by Monika Edlinger Breakdown of academic impact, for papers by Mihai Gheorghe Breakdown of academic impact, for papers by Daniel Bergé Breakdown of academic impact, for papers by Berna Binnur Akdede Breakdown of academic impact, for papers by Aygün Ertuğrul Breakdown of academic impact, for papers by Rebecca Schennach Breakdown of academic impact, for papers by S. R. Marder Breakdown of academic impact, for papers by Anna Mané
Rankless by CCL
2026